ReproCELL Incorporated has finalized the clinical trial implementation plan for its GPC-1 CAR-T therapy. The trial is scheduled to be conducted at Ki-CONNECT at Kyoto University Hospital, and development is progressing with support from AMED. The clinical trial plan is expected to be fleshed out going forward.
ReproCELL Incorporated is reported to have finalized the clinical trial implementation plan for its GPC-1 CAR-T therapy. Ki-CONNECT at Kyoto University Hospital has been identified as the clinical trial site, and the necessary procedures are expected to progress.
The therapy is being developed with support from AMED, the Japan Agency for Medical Research and Development. Further disclosures are awaited regarding the development and progress of the specific clinical trial plan.